Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Pancreatic Cancer Evolution Upon Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05195281
Recruitment Status : Recruiting
First Posted : January 18, 2022
Last Update Posted : January 18, 2022
Information provided by (Responsible Party):
Gabriele Capurso, IRCCS San Raffaele

Brief Summary:

This project aims at evaluating the different subtypes of pancreatic cancer on EUS-tissue acquisition of pancreatic cancer patients, and their possible modifications throughout time. The study takes advantage of a systematic evaluation of pancreatic cancers through diagnostic EUS-guided fine needle biopsy (FNB) sampling of the mass performed during a restaging EUS. FNB samples represent a valuable source of cancer cells, both for the histological diagnosis and as the source of tumor macromolecules, including DNA and RNA.

Study design This is a prospective study enrolling patients with non-metastatic pancreatic cancer who already underwent diagnostic EUS with tissue acquisition and rapid on-site evaluation (ROSE) by cytologist positive for pancreatic cancer, with a first sample acquired for diagnostic purposes and a second sample stored for RNA extraction acquired with the already approved protocol BIOGASTRO.

As recommended by guidelines, patients will follow the standard pathway of treatment, being sent to chemotherapy and will then undergo restaging of the lesion and re-evaluation of vascular invasion by CT and EUS. During this second session of EUS a new specimen of the tumor will be sampled for diagnostic purposes, with a second pass undergoing for RNA extraction.

Condition or disease Intervention/treatment Phase
Pancreatic Cancer Procedure: Fine Needle Biopsy or Aspiration Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Pancreatic Cancer Evolution Upon Treatment
Actual Study Start Date : July 14, 2021
Estimated Primary Completion Date : February 28, 2023
Estimated Study Completion Date : December 31, 2024

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Repetition of EUS-FNA or FNB for RNA extraction Procedure: Fine Needle Biopsy or Aspiration
A new sampling of the tumor will be performed after 4-6 months of neoadjuvant chemotherapy

Primary Outcome Measures :
  1. Evaluation of molecular subtype modification [ Time Frame: 6 months ]
    As all patients are having baseline (at diagnosis) molecular subtype (classical or basal-like) evaluation through RNAsequencing, patients enrolled in the PACEUT trial will undergo a new evaluation of the molecular subtype (based on RNAsequencing performed on the EUS-FNA or FNB) and evaluation of gene expression

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≥ 18 years
  • Willing to sign informed consent
  • Patient with CT scan or MRI or EUS defining the lesion as locally advanced
  • Patient who already underwent EUS-TA for solid lesion of the pancreas positive for pancreatic ductal adenocarcinoma (PDAC)
  • Patient undergoing neoadjuvant chemotherapy
  • Patient primarily followed at San Raffaele Hospital

Exclusion Criteria:

  • Patients not willing to sign informed consent
  • Pregnancy and breastfeeding
  • Cytology positive for malignancies other than PDAC
  • Patient undergoing progression at re-staging CT scan

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05195281

Layout table for location contacts
Contact: Livia Archibugi, MD +39-02-26432471

Layout table for location information
IRCCS San Raffaele Hospital Recruiting
Milan, Italy, 20132
Contact: Livia Archibugi, MD    +39-02-26432471   
Sponsors and Collaborators
IRCCS San Raffaele
Layout table for additonal information
Responsible Party: Gabriele Capurso, Chief of Clinical Research, PancreatoBiliary Endoscopy and EUS Division, Deputy Director of Pancreas Center, IRCCS San Raffaele Identifier: NCT05195281    
Other Study ID Numbers: PACEUT
First Posted: January 18, 2022    Key Record Dates
Last Update Posted: January 18, 2022
Last Verified: January 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases